{"name":"Durata Therapeutics Inc., an affiliate of Allergan plc","slug":"durata-therapeutics-inc-an-affiliate-of-allergan-plc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"IV Dalbavancin","genericName":"IV Dalbavancin","slug":"iv-dalbavancin","indication":"Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria","status":"phase_3"},{"name":"Vancomycin / Linezolid","genericName":"Vancomycin / Linezolid","slug":"vancomycin-linezolid","indication":"Treatment of complicated skin and skin structure infections (cSSSI), including those caused by susceptible Gram-positive bacteria","status":"phase_3"}]}],"pipeline":[{"name":"IV Dalbavancin","genericName":"IV Dalbavancin","slug":"iv-dalbavancin","phase":"phase_3","mechanism":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","indications":["Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria","Staphylococcus aureus bacteremia including endocarditis"],"catalyst":""},{"name":"Vancomycin / Linezolid","genericName":"Vancomycin / Linezolid","slug":"vancomycin-linezolid","phase":"phase_3","mechanism":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria, while Linezolid inhibits protein synthesis by binding to the 50S ribosomal subunit.","indications":["Treatment of complicated skin and skin structure infections (cSSSI), including those caused by susceptible Gram-positive bacteria","Treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQaDNkQVlyX1YyNl91WmZwa2ozdFo1YmhRSlJEREdxb19mNTlrWThIUDhaWVMzRENZcDFFWHMtT0V2ajVZSlNCTS0zck9YcWVYeEl6U0hURlNqeHNDQ2c3amp3NDhGSk5JVUsyWmJ2YzgwaDJlNDllSjI0VWJKSW9US2t1SXN6TDFWTkVEaEx0b2dwVk9wbkg0UG1n?oc=5","date":"2025-10-30","type":"pipeline","source":"BioSpace","summary":"Vistagen Appoints Paul Edick to its Board of Directors - BioSpace","headline":"Vistagen Appoints Paul Edick to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcV9kRks2cXd6Zm1RVm9FXzltUFY3UE82WkgyblRWckRSdm0tX0pXa1czNkFDRGVHSFV4WnhJdDRrV1VjVkRVeVE5cUstUTVxcUliMW9rdU1PQzZEM0FwejhzaEhaT0I2VTZwTEpxN1BRWkthSUhxTTMxY3pDanpYTGhFQ05uZGtoNy0taHNHUWJPWThuRzFxa21wVmpwSU9SWlhmX0RlSQ?oc=5","date":"2025-07-01","type":"pipeline","source":"Bloomberg Law News","summary":"AbbVie Denied Freeze on Tennessee Pharmacy Contract Law (1) - Bloomberg Law News","headline":"AbbVie Denied Freeze on Tennessee Pharmacy Contract Law (1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBQWVhobEZTa3o5TzRzbzRUQm9nSjFOb1lWZE5KUnJkVXlvelZzYUJ4dGhQa0I5djN2NUY5WDdaZUpyOXJIU0pZMFA4VjVPTm5TbFFxX2NEenkzNFhmaDFDREphQlQzVF9pLVpZSVgwQmFWQQ?oc=5","date":"2015-11-24","type":"pipeline","source":"C&EN","summary":"Pfizer, Allergan To Combine - C&EN","headline":"Pfizer, Allergan To Combine - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNFRteWQ4enVKeGRHYV9YendreGtlNF9oNFd0MmYtclBvSWRqeVJaSmg2dDFlWXJDY0xFRzJ6NllKSlZSa1NFWWNOWTh3REp3MzlZR0kzUHUyNFNQWGIwWVJRbXA1VTFfYWtZb2xwaEsxdHI5RkdwLWVad29CeUdKOFhKU0dfZUtCZnhadWNPOVBmQnNGSk9rLTMzT2RFeFk?oc=5","date":"2014-10-06","type":"deal","source":"PR Newswire","summary":"Actavis to Acquire Durata Therapeutics, Inc. - PR Newswire","headline":"Actavis to Acquire Durata Therapeutics, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOR3Y1RzZfbGxPS0FmbVNUb0o4R3djSE1Td3BSMnFMMncwTGxtOUxQdWpMSmhPRFVSSThSLUh4aHRtQ2psRXZVb3VXWHMyZXcwMHQwbnVVVzRJXzZvVEl2QUhoYUppSnZqSHdqeHBsNFVGLUhhNU82LU1rZ3pGTXdJbTZtM0lJRDFjVm4xZ3p3?oc=5","date":"2014-10-06","type":"deal","source":"WSJ","summary":"Actavis Agrees to Buy Antibiotic Maker Durata Therapeutics - WSJ","headline":"Actavis Agrees to Buy Antibiotic Maker Durata Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}